US neurologists prescribing oral MS drug Tecfidera.....

[MSUK]

US neurologists prescribing oral MS drug Tecfidera in growing numbers

BioTrends Research Group finds that, despite being the third oral disease-modifying therapy (DMT) to launch in the U.S. multiple sclerosis (MS) market, 53 percent of surveyed U.S. neurologists have prescribed Biogen Idec's Tecfidera to at least one of their MS patients after only one month on the market. This rate for Tecfidera surpasses that for Novartis's Gilenya (19 percent), the first-to-market oral DMT, and Genzyme's Aubagio (16 percent), the second-to-market oral DMT, at the same stage of product launch.... Read More - http://www.ms-uk.org/index.cfm/BG12